BRISBANE, Calif., Oct. 21, 2008 (GLOBE NEWSWIRE) -- BiPar Sciences, Inc., a privately held biopharmaceutical company developing PARP inhibitors as novel cancer therapies, announced today that John Schembri, BiPar's vice president and chief financial officer, will present information on BiPar's development programs and product pipeline, including the company's lead product candidate, BSI-201 which is in Phase 2 clinical trials, at the 2008 BIO Investor Forum in San Francisco, CA. Mr. Schembri will present on October 30, 2008, at 8:30 a.m. PT at the Palace Hotel located at 2 New Montgomery Street, San Francisco.
